Info
🌱來自: snippets
CRCCHEMOAE
**Bevacizumab AEs: risk of arterial thromboembolic events, including MI and stroke esp in pts with age >=65, hx of angina, stroke, and prior arterial thromboembolic events; GI perforation and wound-healing complications, pulmonary hemorrhage rare, hypertesion, proteinuria with nephrotic syndrome, influsion reaction, CNS events with dizziness and depression **Cetuximab AEs: infusion rnx, pruritus, dry skin, acneiform skin rash, interstitial lung disease <1%, and paronychia when prolonged use **Irinotecan: myelosuppresion, diarrhea (dose-limiting), mild alopecia, and risk of developing GI toxicity if patients has UGTIAI 7/7 genotype **Emphasize the importance of nutrional support (high protein diet) during C/T period.
Siblings
- PANCREATIC_ADJ
- AMPULLA
- ANAL
- APTT
- Comfirmed COVID on ?
- APTTPT
- Adrenal
- BCADJ
- BCADJH
- BCFU
- BCMET
- BMD
- BREASTPE
- Bruising
- CCC
- CHEMOAE
- CRCADJ
- CRCCHEMOAE
- CRCFU
- CRCM
- DTIC
- ESOCA
- ESRD
- EYE
- FL
- GB
- GBM
- GC
- GCA
- GCFU
- GIST
- HBV
- HCC
- HNSCCAE
- HNSCCAECCRT
- HP
- HYPERLIPIDEMIA
- IDA
- INDUCTIONBC
- IO
- ImatinibNIH
- KARNOFSKYPS
- LAP
- LUNGNET
- LUNGNETS
- MEGESTROL
- MYELOMA
- NET
- NSCLC
- NSCLCADJ
- NSCLCFU
- PANCREATIC
- PE
- PEGI
- PGNG
- PLT
- PNET
- RECTALADJ
- RECTALCCRT
- RECTALNET